Generated by AI
Summary of Oct 23's posts. Generated by AI.
Summary of Sep 23's posts. Generated by AI.
Summary of Sep 23's posts. Generated by AI.
Investors talking about GNPX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Genprex Inc. Common Stock is the equity security of Genprex Inc., a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes. The company’s current pipeline centers on gene-based technologies designed to deliver therapeutic genes using non-viral and nanoparticle delivery approaches. Its oncology work includes REQORSA immunogen therapy, which is being developed for lung cancer, while its diabetes program includes GPX-002, a gene therapy candidate aimed at addressing metabolic disease. Genprex Inc. operates in the healthcare and biotechnology sectors, where it contributes to the broader field of advanced genetic medicine and targeted treatment development. The common stock represents investor exposure to a company whose business is built around translational research, drug development, and clinical-stage innovation in diseases with significant unmet medical need.
Website3300 Bee Cave Road
Austin, TX, 78746
United States
The latest articles about GNPX.
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), today announced that members of its executive leadership team will present at and participate in the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14–16 in New York City. Genprex is a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes. The Company's lead oncology program is in clinical developmen